NASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis $3.41 +0.23 (+7.23%) As of 04/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opthea Stock (NASDAQ:OPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Opthea alerts:Sign Up Key Stats Today's Range$3.25▼$3.4850-Day Range$3.07▼$5.9252-Week Range$1.79▼$6.30Volume3,000 shsAverage Volume26,033 shsMarket Capitalization$524.84 millionP/E RatioN/ADividend YieldN/APrice Target$1.33Consensus RatingHold Company OverviewOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More… Remove Ads Opthea Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreOPT MarketRank™: Opthea scored higher than 15% of companies evaluated by MarketBeat, and ranked 895th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingOpthea has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageOpthea has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opthea's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.35% of the float of Opthea has been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.35% of the float of Opthea has been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment-0.14 News SentimentOpthea has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Opthea this week, compared to 3 articles on an average week.MarketBeat Follows5 people have added Opthea to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Opthea's insider trading history. Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Stock News HeadlinesPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2 at 10:04 AM | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31 at 7:09 PM | marketwatch.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Opthea terminates COAST trial, announces ShORe trial misses endpointMarch 31 at 7:09 PM | markets.businessinsider.comOpthea Announces Decision to Discontinue Wet AMD TrialsMarch 31 at 12:01 AM | globenewswire.comOpthea Limited’s Securities Suspended Due to Financial ConcernsMarch 30 at 11:45 PM | tipranks.comJPMorgan Chase Acquires Substantial Stake in Opthea LimitedMarch 30 at 5:53 PM | tipranks.comFY2025 EPS Estimates for Opthea Reduced by Leerink PartnrsMarch 29, 2025 | americanbankingnews.comSee More Headlines OPT Stock Analysis - Frequently Asked Questions How have OPT shares performed this year? Opthea's stock was trading at $3.93 at the start of the year. Since then, OPT stock has decreased by 13.2% and is now trading at $3.41. View the best growth stocks for 2025 here. When did Opthea IPO? Opthea (OPT) raised $161 million in an initial public offering on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. How do I buy shares of Opthea? Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST) and Zendesk (ZEN). Company Calendar Today4/02/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPT CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$1.33 High Stock Price Target$2.00 Low Stock Price Target$1.00 Potential Upside/Downside-60.9%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual Sales$87,666.00 Price / Sales5,986.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.56) per share Price / Book-6.09Miscellaneous Outstanding Shares153,911,000Free Float148,981,000Market Cap$524.84 million OptionableNot Optionable Beta1.12 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OPT) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.